Trial Profile
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab "
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DARA for myeloma
- 04 Jan 2017 Status changed from recruiting to completed.
- 18 Mar 2015 New trial record